For Patients: Clinical Trials
Publications
Careers
Contact Us
Toggle navigation
About INOVIO
Purpose, Mission and Values
Leadership
Partnerships
DNA Medicines Technology
Optimized Plasmid Design and Delivery
DNA Medicines Explained
The Promise of DNA Medicine
NEXT GEN DNA MEDICINE
DNA Medicines Pipeline
Investors & Media
Events & Presentations
Stock Information
News Releases
SEC Filings
Analyst Coverage
Corporate Governance
Shareholder Services
FAQ
For Patients: Clinical Trials
Publications
Careers
Contact Us
About INOVIO
Purpose, Mission and Values
Leadership
Partnerships
DNA Medicines Technology
Optimized Plasmid Design and Delivery
DNA Medicines Explained
The Promise of DNA Medicine
NEXT GEN DNA MEDICINE
DNA Medicines Pipeline
Investors & Media
Events & Presentations
Stock Information
News Releases
SEC Filings
Analyst Coverage
Corporate Governance
Shareholder Services
FAQ
For Patients: Clinical Trials
Publications
Careers
Contact Us
Press Releases
INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference
Posted on November 15, 2021
INOVIO Reports Third Quarter 2021 Financial Results
Posted on November 9, 2021
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
Posted on November 9, 2021
INOVIO Expands Executive Leadership to Prepare for Commercial Operations
Posted on November 5, 2021
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India
Posted on November 3, 2021
INOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021
Posted on October 27, 2021
INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa
Posted on October 26, 2021
INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives
Posted on October 21, 2021
INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800
Posted on October 12, 2021
INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
Posted on October 11, 2021
Page 11 of 16
« First
«
...
9
10
11
12
13
...
»
Last »
© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.